POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

FDA urged to let abortion pill be sold at pharmacies

Staff Writer |
The so-called abortion pill should be made available by prescription in pharmacies across the U.S., according to a group of doctors and public health experts urging an end to tough federal restrictions on the drug.

Article continues below






The appeal to the Food and Drug Administration came in a commentary published in the New England Journal of Medicine.

Among the 10 co-authors were doctors and academics from Stanford, Princeton and Columbia universities, as well as leaders of major reproductive-health organizations.

The restrictions have been in place since the drug, mifepristone, was approved for use in the U.S. in 2000.

They stipulate that the drug, marketed as Mifeprex, may not be sold in pharmacies and that all providers of the drug undergo a special certification process.

"The restrictions on mifepristone are a shameful example of overregulation run amok," said one of the authors, Dr. Beverly Winikoff of the New York-based research organization Gynuity Health Projects.

"Women and their health providers shouldn't have to jump through hoops to get a medication that's been safely and effectively used in this country for a decade and a half."

According to the commentary, 19 deaths have been reported to the FDA among the more than 3 million women who've used Mifeprex in the U.S. since 2000, a mortality rate lower than for pregnancy-related deaths among women.

Asked about the commentary, the FDA's media office referred a reporter to a 2016 document asserting that the restrictions on Mifeprex remain necessary for safety reasons.

According to the latest federal figures, medical abortions—generally a two-pill regimen using Mifeprex and the drug misoprostol—accounted for about 22 percent of abortions in the U.S. in 2013. Surgical procedures accounted for nearly all the other abortions.

The new commentary suggested that lifting the FDA restrictions would likely increase the number of doctors willing to prescribe Mifeprex, since they would no longer have to stock the drug in their office and would no longer have to be on a list of certified abortion providers.

Easing the rules also might help make medical abortion more available via telemedicine to women in rural areas who live far from the nearest abortion facility, the authors said.


What to read next

New pill offers hope to hepatitis C patients who fail other treatment
Australian papaya pill offers hope of relief to gluten-intolerance
Men, avoid impotence drugs before surgery